Psoriasis
https://en.wikipedia.org/wiki/Psoriasis
☆ AI Dermatology — Free ServiceDina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar. relevance score : -100.0%
References
Psoriasis 28846344 NIH
Phototherapy 33085287 NIH
Tumor Necrosis Factor Inhibitors 29494032 NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).
Rupa‑rupa pangobatan tiasa ngabantosan ngontrol gejala. Pangobatan ieu kalebet krim steroid, krim vitamin D3, sinar ultraviolét, sareng obat imunosupresif, sapertos methotrexate. Sakitar 75 % tina keterlibatan kulit ningkat ku krim sorangan. Rupa‑rupa agen imunologis biologis geus dimekarkeun pikeun pengobatan psoriasis.
Psoriasis mangrupikeun gangguan umum anu mangaruhan 2‑4 % populasi. Lalaki sareng awéwé kapangaruhan ku frékuénsi anu sami. Panyakit ieu tiasa muncul dina sagala umur, tapi ilaharna dimimitian dina dewasa. Psoriatic arthritis mangaruhan nepi ka 30 % jalma kalayan psoriasis.
○ Perawatan – Obat OTC
Cahaya panonpoé tiasa ngabantosan psoriasis sabab paparan panonpoé ngabalukarkeun parobahan imunologis dina penderita psoriasis. Salep hydrocortisone hampang tiasa ngabantosan pikeun ngubaran sababaraha lesi leutik psoriasis.
#OTC steroid ointment
○ Perawatan
Psoriasis mangrupikeun panyakit kronis sareng aya seueur agen pangobatan anu dipaké. Agen biologis paling efektif, tapi mahal pisan.
#High potency steroid ointment
#Calcipotriol cream
#Phototherapy
#Biologics (e.g. infliximab, adalimumab, secukinumab, ustekinumab)